We assess the burden of functionally impactful variants present in ERAP1 and ERAP2 in 2 cohorts of patients diagnosed with inflammatory bowel disease (IBD; Crohn’s disease (CD) or ulcerative colitis (UC)). This evidence concerns the gene ERAP2 and ulcerative colitis.